A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo

The lack of animal models for some human diseases precludes our understanding of disease mechanisms and our ability to test new therapies in vivo. Here the authors present a tissue bioengineering strategy for the study of a rare kidney tumor called angiomyolipoma, in vitro and in vivo, using patient...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	J. O. R. Hernandez, X. Wang, M. Vazquez-Segoviano, M. Lopez-Marfil, M. F. Sobral-Reyes, A. Moran-Horowich, M. Sundberg, D. O. Lopez-Cantu, C. K. Probst, G. U. Ruiz-Esparza, K. Giannikou, R. Abdi, E. P. Henske, D. J. Kwiatkowski, M. Sahin, D. R. Lemos
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/928c67a16e704b9e921c20f97413c1e4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:928c67a16e704b9e921c20f97413c1e4
record_format	dspace
spelling	oai:doaj.org-article:928c67a16e704b9e921c20f97413c1e42021-11-14T12:35:14ZA tissue-bioengineering strategy for modeling rare human kidney diseases in vivo10.1038/s41467-021-26596-y2041-1723https://doaj.org/article/928c67a16e704b9e921c20f97413c1e42021-11-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-26596-yhttps://doaj.org/toc/2041-1723The lack of animal models for some human diseases precludes our understanding of disease mechanisms and our ability to test new therapies in vivo. Here the authors present a tissue bioengineering strategy for the study of a rare kidney tumor called angiomyolipoma, in vitro and in vivo, using patient-derived hiPSCs.J. O. R. HernandezX. WangM. Vazquez-SegovianoM. Lopez-MarfilM. F. Sobral-ReyesA. Moran-HorowichM. SundbergD. O. Lopez-CantuC. K. ProbstG. U. Ruiz-EsparzaK. GiannikouR. AbdiE. P. HenskeD. J. KwiatkowskiM. SahinD. R. LemosNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q J. O. R. Hernandez X. Wang M. Vazquez-Segoviano M. Lopez-Marfil M. F. Sobral-Reyes A. Moran-Horowich M. Sundberg D. O. Lopez-Cantu C. K. Probst G. U. Ruiz-Esparza K. Giannikou R. Abdi E. P. Henske D. J. Kwiatkowski M. Sahin D. R. Lemos A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo
description	The lack of animal models for some human diseases precludes our understanding of disease mechanisms and our ability to test new therapies in vivo. Here the authors present a tissue bioengineering strategy for the study of a rare kidney tumor called angiomyolipoma, in vitro and in vivo, using patient-derived hiPSCs.
format	article
author	J. O. R. Hernandez X. Wang M. Vazquez-Segoviano M. Lopez-Marfil M. F. Sobral-Reyes A. Moran-Horowich M. Sundberg D. O. Lopez-Cantu C. K. Probst G. U. Ruiz-Esparza K. Giannikou R. Abdi E. P. Henske D. J. Kwiatkowski M. Sahin D. R. Lemos
author_facet	J. O. R. Hernandez X. Wang M. Vazquez-Segoviano M. Lopez-Marfil M. F. Sobral-Reyes A. Moran-Horowich M. Sundberg D. O. Lopez-Cantu C. K. Probst G. U. Ruiz-Esparza K. Giannikou R. Abdi E. P. Henske D. J. Kwiatkowski M. Sahin D. R. Lemos
author_sort	J. O. R. Hernandez
title	A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo
title_short	A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo
title_full	A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo
title_fullStr	A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo
title_full_unstemmed	A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo
title_sort	tissue-bioengineering strategy for modeling rare human kidney diseases in vivo
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/928c67a16e704b9e921c20f97413c1e4
work_keys_str_mv	AT jorhernandez atissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT xwang atissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT mvazquezsegoviano atissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT mlopezmarfil atissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT mfsobralreyes atissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT amoranhorowich atissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT msundberg atissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT dolopezcantu atissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT ckprobst atissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT guruizesparza atissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT kgiannikou atissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT rabdi atissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT ephenske atissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT djkwiatkowski atissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT msahin atissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT drlemos atissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT jorhernandez tissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT xwang tissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT mvazquezsegoviano tissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT mlopezmarfil tissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT mfsobralreyes tissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT amoranhorowich tissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT msundberg tissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT dolopezcantu tissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT ckprobst tissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT guruizesparza tissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT kgiannikou tissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT rabdi tissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT ephenske tissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT djkwiatkowski tissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT msahin tissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo AT drlemos tissuebioengineeringstrategyformodelingrarehumankidneydiseasesinvivo
_version_	1718429118768349184

A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo

Ejemplares similares